T1	CHEM 46 56	lamivudina
#1	AnnotatorNotes T1	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T2	CHEM 57 66	tenofovir
#2	AnnotatorNotes T2	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T3	CHEM 69 78	efavirenz
#3	AnnotatorNotes T3	C0674428; efavirenz; Organic Chemical · Pharmacologic Substance
T4	DISO 100 104	SIDA
#4	AnnotatorNotes T4	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T5	PROC 112 143	estudio fase IV no aleatorizado
#5	AnnotatorNotes T5	C0282462; Phase 4 Clinical Trials; Research Activity + C2985410; Non-Randomized Controlled Trials as Topic; Research Activity
T6	PROC 189 206	estudios clínicos
#6	AnnotatorNotes T6	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T7	PROC 940 985	parámetros inmunovirológicos y de laboratorio
T8	CHEM 242 264	medicamentos genéricos
#7	AnnotatorNotes T8	C0085155; Generic Drugs; Pharmacologic Substance
T9	PROC 321 354	terapia anti-retroviral combinada
#8	AnnotatorNotes T9	C5545321; Combination Antiretroviral Therapy; Therapeutic or Preventive Procedure
T10	PROC 356 360	TARc
#9	AnnotatorNotes T10	C5545321; Combination Antiretroviral Therapy; Therapeutic or Preventive Procedure
T11	CHEM 433 443	lamivudina
#10	AnnotatorNotes T11	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T12	CHEM 444 453	tenofovir
#11	AnnotatorNotes T12	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T13	CHEM 454 463	efavirenz
#12	AnnotatorNotes T13	C0674428; efavirenz; Organic Chemical · Pharmacologic Substance
T14	CHEM 465 468	3TC
#13	AnnotatorNotes T14	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T15	DISO 495 512	infección por VIH
#14	AnnotatorNotes T15	C0019693; HIV Infections; Disease or Syndrome
T16	DISO 513 517	SIDA
#15	AnnotatorNotes T16	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T17	PROC 598 661	Estudio clínico prospectivo fase IV abierto y sin grupo control
T18	PROC 696 705	siguieron
#16	AnnotatorNotes T18	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T19	PROC 816 824	tratados
#17	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	DISO 723 740	infección por VIH
#18	AnnotatorNotes T20	C0019693; HIV Infections; Disease or Syndrome
T21	DISO 741 745	SIDA
#19	AnnotatorNotes T21	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T22	PROC 782 793	tratamiento
#20	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 849 852	3TC
#21	AnnotatorNotes T23	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T24	PROC 900 911	seguimiento
#22	AnnotatorNotes T24	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T25	CHEM 1672 1675	TDF
#23	AnnotatorNotes T25	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T26	PROC 920 938	valoración clínica
#24	AnnotatorNotes T26	C4534461; Clinical assessment; Health Care Activity
T27	PROC 1001 1012	tratamiento
#25	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	PROC 1111 1122	tratamiento
#26	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	PROC 1146 1148	CV
#27	AnnotatorNotes T29	C1261478; Viral load measurement; Laboratory Procedure
T30	PROC 1187 1189	CV
#28	AnnotatorNotes T30	C1261478; Viral load measurement; Laboratory Procedure
T31	CHEM 1676 1679	EFV
#29	AnnotatorNotes T31	C0674428; efavirenz; Organic Chemical · Pharmacologic Substance
T32	ANAT 1274 1289	linfocitos TCD4
#30	AnnotatorNotes T32	C0039215; CD4 Positive T Lymphocytes; Cell
T33	PROC 1328 1346	hemograma completo
#31	AnnotatorNotes T33	C0009555; Complete Blood Count; Laboratory Procedure
T34	PROC 1348 1361	creatininemia
#32	AnnotatorNotes T34	C0201975; Creatinine measurement; Laboratory Procedure
T35	CHEM 1364 1377	transaminasas
#33	AnnotatorNotes T35	C0002594; Transaminases; Amino Acid, Peptide, or Protein · Enzyme
T36	ANAT 1378 1387	hepáticas
#34	AnnotatorNotes T36	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T38	DISO 1459 1475	efectos adversos
#35	AnnotatorNotes T38	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T39	CHEM 1499 1511	medicamentos
#36	AnnotatorNotes T39	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T40	CHEM 1668 1671	3TC
#37	AnnotatorNotes T40	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T41	PROC 1707 1718	tratamiento
#38	AnnotatorNotes T41	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T42	DISO 1736 1753	infección por VIH
#39	AnnotatorNotes T42	C0019693; HIV Infections; Disease or Syndrome
T43	DISO 1754 1758	SIDA
#40	AnnotatorNotes T43	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T44	CHEM 1831 1834	3TC
#41	AnnotatorNotes T44	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T45	DISO 96 99	VIH
#42	AnnotatorNotes T45	C0458074; Human immunodeficiency virus (HIV) status; Finding
T46	CHEM 469 472	TDF
#43	AnnotatorNotes T46	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T47	CHEM 853 856	TDF
#44	AnnotatorNotes T47	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T48	PROC 1364 1387	transaminasas hepáticas
#45	AnnotatorNotes T48	C0919834; Transaminase Assay; Laboratory Procedure
T49	CHEM 473 476	EFV
#46	AnnotatorNotes T49	C0674428; efavirenz; Organic Chemical · Pharmacologic Substance
T50	PROC 545 574	programa de atención integral
T51	CHEM 857 860	EFV
#47	AnnotatorNotes T51	C0674428; efavirenz; Organic Chemical · Pharmacologic Substance
T52	PROC 870 878	seguidos
#48	AnnotatorNotes T52	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T53	CHEM 1835 1838	TDF
#49	AnnotatorNotes T53	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T54	CHEM 1839 1842	EFV
#50	AnnotatorNotes T54	C0674428; efavirenz; Organic Chemical · Pharmacologic Substance
T55	Date 159 163	2012
T56	Date 164 168	2014
T57	Date 669 673	2012
T58	Date 674 678	2014
T59	Duration 887 895	12 meses
T60	Duration 1017 1036	los 3, 6 y 12 meses
T61	Duration 1093 1107	los doce meses
T63	Neg_cue 1424 1426	no
T64	Neg_cue 1562 1564	no
T65	Neg_cue 644 647	sin
T66	LIVB 82 91	pacientes
#51	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T67	LIVB 481 490	pacientes
#52	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	LIVB 709 718	pacientes
#53	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group
T69	LIVB 1062 1071	pacientes
#54	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	LIVB 1550 1559	pacientes
#55	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T71	LIVB 1637 1646	pacientes
#56	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T72	LIVB 1856 1865	pacientes
#57	AnnotatorNotes T72	C0030705; Patients; Patient or Disabled Group
T73	LIVB 509 512	VIH
#58	AnnotatorNotes T73	C0019682; HIV; Virus
T74	LIVB 737 740	VIH
#59	AnnotatorNotes T74	C0019682; HIV; Virus
T75	LIVB 799 808	pacientes
#60	AnnotatorNotes T75	C0030705; Patients; Patient or Disabled Group
T76	LIVB 1750 1753	VIH
#61	AnnotatorNotes T76	C0019682; HIV; Virus
T77	LIVB 1722 1731	pacientes
#62	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group
T37	PROC 1449 1453	TARc
#63	AnnotatorNotes T37	C5545321; Combination Antiretroviral Therapy; Therapeutic or Preventive Procedure
T78	CONC 1437 1444	cambios
T79	LIVB 648 661	grupo control
#64	AnnotatorNotes T79	C0009932; Control Groups; Group
T81	Quantifier_or_Qualifier 105 110	naïve
T82	Quantifier_or_Qualifier 518 523	naïve
T83	Quantifier_or_Qualifier 746 751	naïve
T84	Result_or_Value 1149 1161	indetectable
T85	Quantifier_or_Qualifier 1759 1764	naïve
T86	Observation 1574 1594	implicaciones graves
T80	CONC 990 1012	inicio del tratamiento
A1	Assertion T79 Negated
R1	Has_Duration_or_Interval Arg1:T28 Arg2:T61
R2	Has_Duration_or_Interval Arg1:T24 Arg2:T60
R4	Has_Duration_or_Interval Arg1:T52 Arg2:T59
R5	After Arg1:T5 Arg2:T55
R6	Before Arg1:T5 Arg2:T56
R7	After Arg1:T18 Arg2:T57
R8	Before Arg1:T18 Arg2:T58
R9	Combined_with Arg1:T1 Arg2:T2
R10	Combined_with Arg1:T2 Arg2:T3
R11	Experiences Arg1:T66 Arg2:T45
R12	Experiences Arg1:T66 Arg2:T4
R13	Used_for Arg1:T8 Arg2:T9
R14	Used_for Arg1:T8 Arg2:T10
R15	Causes Arg1:T73 Arg2:T15
R16	Experiences Arg1:T67 Arg2:T15
R17	Experiences Arg1:T67 Arg2:T16
R18	Combined_with Arg1:T11 Arg2:T12
R19	Combined_with Arg1:T12 Arg2:T13
R20	Combined_with Arg1:T14 Arg2:T46
R21	Combined_with Arg1:T46 Arg2:T49
R24	Causes Arg1:T74 Arg2:T20
R25	Experiences Arg1:T68 Arg2:T20
R26	Experiences Arg1:T68 Arg2:T21
R28	Causes Arg1:T39 Arg2:T38
R29	Negation Arg1:T65 Arg2:T79
R31	Experiences Arg1:T70 Arg2:T38
R32	Combined_with Arg1:T40 Arg2:T25
R33	Combined_with Arg1:T25 Arg2:T31
R34	Used_for Arg1:T31 Arg2:T41
R35	Experiences Arg1:T77 Arg2:T42
R36	Experiences Arg1:T77 Arg2:T43
R37	Causes Arg1:T76 Arg2:T42
R38	Combined_with Arg1:T44 Arg2:T53
R39	Combined_with Arg1:T53 Arg2:T54
R40	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T81
R41	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T82
R43	Experiences Arg1:T68 Arg2:T22
R44	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T83
R45	Experiences Arg1:T75 Arg2:T19
R46	Combined_with Arg1:T23 Arg2:T47
R47	Combined_with Arg1:T47 Arg2:T51
R49	Experiences Arg1:T69 Arg2:T28
R50	Has_Result_or_Value Arg1:T29 Arg2:T84
R51	Experiences Arg1:T71 Arg2:T41
R52	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T85
R27	Negation Arg1:T63 Arg2:T78
R23	Negation Arg1:T64 Arg2:T86
A2	Assertion T86 Negated
A3	Assertion T78 Negated
R53	Used_for Arg1:T23 Arg2:T19
R54	Experiences Arg1:T66 Arg2:T3
R55	Experiences Arg1:T67 Arg2:T49
R56	Experiences Arg1:T70 Arg2:T39
R57	Causes Arg1:T74 Arg2:T21
R58	Causes Arg1:T76 Arg2:T43
R59	Experiences Arg1:T72 Arg2:T54
R60	Has_Duration_or_Interval Arg1:T27 Arg2:T60
R61	Location_of Arg1:T36 Arg2:T48
R30	Experiences Arg1:T70 Arg2:T86
R62	Experiences Arg1:T77 Arg2:T41
R63	Experiences Arg1:T67 Arg2:T13
R64	Overlap Arg1:T26 Arg2:T60
R3	Overlap Arg1:T7 Arg2:T60
R22	Experiences Arg1:T69 Arg2:T29
R42	Experiences Arg1:T69 Arg2:T30
R67	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T82
R68	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T81
R69	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T83
R70	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T85
T62	Quantifier_or_Qualifier 131 143	aleatorizado
A4	Assertion T62 Negated
T87	Neg_cue 128 130	no
R48	Negation Arg1:T87 Arg2:T62	
R71	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T62	
R65	Overlap Arg1:T26 Arg2:T80	
R66	Overlap Arg1:T7 Arg2:T80	
R72	Causes Arg1:T73 Arg2:T16	
#65	AnnotatorNotes T78	C0443172; Changed status; Quantitative Concept
R74	Experiences Arg1:T71 Arg2:T42	
R75	Experiences Arg1:T71 Arg2:T43	
R76	Experiences Arg1:T72 Arg2:T41	
R77	Experiences Arg1:T72 Arg2:T42	
R78	Experiences Arg1:T72 Arg2:T43	
R73	Used_for Arg1:T44 Arg2:T41	
R79	Experiences Arg1:T71 Arg2:T40	
#66	AnnotatorNotes T84	C3827727; Undetectable; Clinical Attribute
A5	Experiencer T66 Patient
A6	Experiencer T67 Patient
A7	Experiencer T79 Other
A8	Experiencer T68 Patient
A9	Experiencer T75 Patient
A10	Experiencer T69 Patient
A11	Experiencer T70 Patient
A12	Experiencer T71 Patient
A13	Experiencer T77 Patient
A14	Experiencer T72 Patient
